A Clinical Study of the Safety and Tolerability of Live Nasal Vaccines for the Prevention of Pertussis

Introduction. Due to the growth of laboratory-confirmed cases of pertussis among adolescents and adults, the spread of latent form of disease and the identification of asymptomatic carriage of the pathogen, the need arose to create a new vaccine against B. pertussis. On the basis of N. F. Gamaleya Federal Research Center for Epidemiology & Microbiology, a pertussis vaccine, containing attenuated B. pertussus bacteria, was developed. The article presents data on a clinical trial of the first phase of the pertussis vaccine “GumGVK, live intranasal vaccine for the prevention of pertussis” in healthy volunteers. Based on the results of the study, data shows the safety and tolerability of the first intranasal vaccine using on humans.

Aim. To Study the safety and tolerability of the vaccine "GamGVK, live vaccine for intranasal use for the prevention of whooping cough»

Materials and methods. Volunteers who expressed a desire to participate in the study were informed about its goals and objectives, conditions and requirements for participants, including the criteria for their inclusion/exclusion from the study. After signing the informed consent, the volunteers were screened for their compliance with the inclusion criteria. Screening studies and safety assessment of the drug were performed on the basis of anamnesis, subjective complaints, assessment of vital signs, ECG, peak flowmetry, results of laboratory tests of urine and blood, enzyme immunoassay of blood serum, analysis of nasopharyngeal aspirates for the presence of pertussis pathogen DNA, results of physical examination.

Results and discussion. The study involved 36 "healthy" volunteers aged 18–40 years. The average age of the volunteers was 26.2 ± 5.5 years. Not reliably identified AES associated with the use of GumGVK. None of the used doses of the drug led to the formation of local and General allergic reactions to intranasal administration of GumGVK.

Conclusions. The drug GumGVK is safe for nasal use, has good tolerance.

pertussis, live vaccine, anti-pertussis vaccine

1. Locht C. Pertussis: Where did we go wrong and what can we do about it? J. of infection. 2016;72:34–40. DOI: 10.1016/j.jinf.2016.04.020.

2. Wood N., McIntyre P. Pertussis: review of epidemiology, diagnosis, management and prevention. Paediatr Respir Rev. 2008;9(3):201– 211. DOI: 10.1016/j.prrv.2008.05.010.

3. Wiley K. E., Zuo Y., Macartney K. K., McIntyre P. B. Sources of pertussis infection in young infants: a review of key evidence informing targeting of the cocoon strategy. Vaccine. 2013;31(4):618–625. DOI: 10.1016/j.vaccine.2012.11.052.

4. Wendelboe A. M., Njamkepo E., Bourillon A. et al. Transmission of Bordetella pertussis to young infants. Pediatr Infect DisJ. 2007;26(4):293–299. DOI: 10.1097/01.inf.0000258699.64164.6d.

5. Medkova A. Yu., Alyapkina Yu. S., Sinyashina L. N., Amelina I. P., Alekseev Ya. I., Karataev G. I., Bokovoy A. G. The prevalence of subclinical forms of pertussis and analysis of phase states of bacteria Bordetella pertussis. Detskie infekcii = CHILDREN INFECTIONS. 2010;9(4):19–22. (In Russ.).

6. Centers for Disease Control and Prevention (CDC). Pertussis epidemic – Washington, 2012. MMWR Morb Mortal Wkly Rep. 2012;61(28):517–522.

7. Rosewell A., Spokes P. J., Gilmour R. E. NSW Annual vaccine-preventable disease report, 2011. NSW Public Health Bull. 2012;23(9-10):171–178. DOI: 10.1071/NB12086.

8. Gonfiantini M. V., Carloni E., Gesualdo F. et al. Epidemiology of pertussis in Italy: disease trends over the last century. Eurosurveillance. 2014;19(40):20921. DOI: 10/2807/1560-7917.es2014.19.40.20921.

9. Confirmed pertussis in England and Wales: data to end – November 2012. Health Protection report. London. 2012;126(51). Available at: http://www.hpa.org.uk/hpr/archives/2012/news5112.htm#prtsss1211.

10. Iozefovich O. V., Kharit S. M., Kaplina S. P., Gostev V. V., Sidorenko S. V., Kalinogorskaya O. S., Kvetnaya A. S., Timofeeva E. V., Okuneva M. A. Rasprostranjonnost’ kokljusha u dlitel’no kashljajushhih detej 6–17 let, privityh v rannem vozraste AKDS-vakcinoj [The prevalence of pertussis in long coughing children 6–17 years old, vaccinated at an early age with DTP vaccine]. Jepidemiologija i vakcinoprofilaktika. 2012;5(66):56–59. (In Russ.).

11. Lobzin Ju. V., Harit S. M. Problemy vakcinoprofilaktiki: kratkaja istorija, sovremennoe sostojanie i puti reshenija [Problems of Vaccine Prevention: A Brief History, Current State and Solutions]. Èpidemiologiâ i infekcionnye bolezni. Aktual’nye voprosy = Epidemiology and Infectious Diseases. 2014;6:30–37. (In Russ.).

12. Warfel J. M., Zimmerman L. I., Merkel T. J. Acellular pertussis vaccines protect against disease but fail to prevent infection and transmission in a nonhuman primate model. Proc. Natl. Acad. Sci. USA. 2014;111(2):787–792. DOI: 10/1073/pnas.1314688110.

13. Kilgore P. E., Salim A. M., Zervos M. J., Schmitt H. J. Pertussis: Micro-biology, Disease, Treatment, and Prevention. Clinical Microbiology Rev. 2016;29(3):449–486. DOI: 10.1128/CMR.00083-15.

14. Chen Z., He Q. Immune persistence after pertussis vaccination. Hum Vaccin Immunother. 2017;13(4):744–756. DOI: 10.1080/21645515.2016.1259780.

15. Guiso N., Njamkepo E., Vié le Sage F. et al. Long-term humoral and cell-mediated immunity after acellular pertussis vaccination compares favourably with whole-cell vaccines 6 years after booster vaccination in the second year of life. Vaccine. 2007;25(8):1390–1397. DOI: 10.1016/j.vaccine.2006.10.048.

16. Wendelboe A. M., Njamkepo E., Bourillon A. et al. Transmission of Bordetella pertussis to young infants. Pediatr Infect Dis J. 2007;26(4):293–299. DOI: 10/1097/01.inf.0000258699.64164.6d.

17. Tanaka M., Vitek C. R., Pascual F. B. et al. Trends in pertussis among infants in the United States. 1980–1999. JAMA. 2003;290(22):2968–2975. DOI: 10/1001/jama.290.22.2968.

18. Common Terminology Criteria for Adverse Events (CTCAE) Version 4 Published: May 28, 2009 (v4.03: June 14, 2010). U.S. Department of health and human services.